Navigation Links
Alseres Pharmaceuticals' Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial
Date:9/24/2007

contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements include statements regarding Alseres Pharmaceuticals, Inc. future expectations, beliefs, intentions, goals, strategies, plans or prospects regarding the future, including the development and commercialization of ALTROPANE and Cethrin, the prospects of the Company's CNS therapeutics program, the Company's strategies to develop and commercialize axon regeneration technologies and the breadth of the Company's technologies and intellectual property portfolio. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including those risks, uncertainties and factors referred to in the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2007 filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Alseres Pharmaceuticals, Inc. from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. Alseres Pharmaceuticals, Inc. is providing the information in this press release as of this date and assumes no obligations to update the information in this press release.

Contact:

Sharon Correia

Director, Corporate Communications

scorreia@alseres.com

508-497-23
'/>"/>

SOURCE Alseres Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Calif. , Aug. 27, 2015 ... milestone in the commercial development of the company,s ... The Smart Oxygen device, being developed by ieCrowd,s ... to a patient,s changing demand for oxygen based ... the 510 (k) submission for the Smart Oxygen ...
(Date:8/27/2015)... , Aug. 27, 2015  Eli Lilly and Company ... Global Healthcare Conference on Thursday, September 17, 2015. ... of Lilly Oncology and Richard Gaynor , M.D., ... for Lilly Oncology, will participate in a fireside chat ... A live audio webcast will be available on the ...
(Date:8/27/2015)... Aug. 27, 2015   Women Grow , the fastest-growing professional ... partnering with the Cannabis World Congress & Business Exposition ... produce 15 business-focused educational sessions. CWCBExpo in LA will take ... Convention Center in Los Angeles, CA ... West Coast for the marijuana industry. The Women ...
Breaking Medicine Technology:Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 2Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 3Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 4Lilly to Participate in Morgan Stanley Global Healthcare Conference 2Cannabis World Congress in Los Angeles Boasts Women Grow Sponsored Education 2Cannabis World Congress in Los Angeles Boasts Women Grow Sponsored Education 3Cannabis World Congress in Los Angeles Boasts Women Grow Sponsored Education 4
... NKTR ) today announced positive results from ... study evaluating single-agent NKTR-102 in women with platinum-resistant/refractory ovarian ... with prior Doxil® (pegylated liposomal doxorubicin or PLD) treatment ... criteria (response by tumor imaging) or Gynecologic Cancer InterGroup ...
... CHICAGO and SAN FRANCISCO, June 4, 2011 ... announced positive results from a Phase 2 clinical ... third-line treatment in patients with metastatic breast cancer ... Meeting (ASCO).  NKTR-102, a next-generation topoisomerase I inhibitor, ...
Cached Medicine Technology:NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 2NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 3NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 4NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 5NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 6NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 7NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 8NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting 2NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting 3NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting 4NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting 5NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting 6NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting 7NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting 8NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting 9
(Date:8/30/2015)... Raton, Fl (PRWEB) , ... August 30, 2015 , ... ... to have beneficial effects as sleep aids and calming remedies, which help to improve ... the result of a great deal of research in the field of regenerative medicine ...
(Date:8/29/2015)... ... August 30, 2015 , ... Rio Salado College President Chris Bustamante ... Vice President of Strategic Initiatives and Information Services. O’Shea, who has served Rio Salado ... its reach and impact through innovative technologies and strategies. , “I am very proud ...
(Date:8/29/2015)... ... August 29, 2015 , ... ... support and protection against dribbled urine and sweat. "In order to prevent these ... , The EASY ACCESS DRYNESS ENHANCED MEN'S UNDERGARMENT provides optimal support for a ...
(Date:8/29/2015)... Aliso Viejo, CA (PRWEB) , ... August 29, 2015 , ... ... Cut Pro X . Each preset contains 15 seconds of unique footage that users ... presets that rise, fall, zoom, attract and more. Users can customize color, brightness, scale, ...
(Date:8/28/2015)... (PRWEB) , ... August 29, 2015 , ... Rio ... higher learning and the student experience as part of the EDUCAUSE - Next Generation ... Foundation . , This is the third Breakthrough Models Incubator hosted by ...
Breaking Medicine News(10 mins):Health News:Creative Medical Health’s Natural Rest® Now Available on ReCreative Medical Health’s Natural Rest® Now Available on RevNutrition.com 2Health News:Rio Salado College Appoints New Vice President of Strategic Initiatives and Information Services 2Health News:Modified Men’s Underwear Promote More Comfort and Hygiene - Designed by InventHelp Client (LGI-1968) 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4
... strikes a chord ... with frustrated women, SALT LAKE CITY, March 12 ... undertones., "I love the commercial because sometimes my husband remembers to ... make any,difference," says a customer service rep (who wishes to remain anonymous),at ...
... in U.S. may block brain receptor among some users ... weight-loss drug rimonabant has been associated with troubling psychiatric ... why. , A receptor in the brain called TRPV1, ... blocked by large doses of rimonabant (Acomplia), resulting in ...
... IVF Success, NEWBURGH, N.Y., March 12 ... Mount Sinai Hospital, is proud to introduce,premier fertility ... of,Reproductive Endocrinologist Jeffrey Klein, M.D. to its medical ... Westchester division of,Reproductive Medicine Associates (RMA) of New ...
... Institutets Board of Research confers the title honorary doctor ... have promoted activities carried out at the university. This ... conferred. The ceremony will take place on Friday 9 ... honorary doctors will receive their doctoral hats, diplomas and ...
... that restores a missing liver enzyme in test animals ... in humans, according to Duke University Medical Center researchers. ... disease type Ia (GSD-Ia), cant make an enzyme that ... that all cells use for energy. Without treatment, their ...
... Founders donating stock to establish corporate foundation; Community ... program helps care for the aging in Bay ... Caring.com is pleased to,announce its participation as the ... dedicated to engaging high-growth,companies in corporate citizenship and ...
Cached Medicine News:Health News:An Important Message to Anyone Taking Viagra ... From The Women Who Love You ... and Zoller Labs 2Health News:Possible Reason for Rimonabant's Side Effects Discovered 2Health News:Possible Reason for Rimonabant's Side Effects Discovered 3Health News:SLCH Brings Infertility Specialist to Region 2Health News:3 new honorary doctors at Karolinska Institutet 2Health News:Gene therapy could save kids from a lifetime of eating cornstarch 2Health News:Gene therapy could save kids from a lifetime of eating cornstarch 3Health News:Caring.com Joins Entrepreneurs Foundation as 200th Member 2
200 L, Racked, Filtered, Pre-sterilized, 96 tips/rack Recommended for 20, 25, 50, 100 and 200 L pipettes. Can also be used with 300 L pipettes when pipetting 200 L or less....
... aerosol contamination, which causes ... PCR. Hydrophobic, nonwicking and ... can pass through these ... contrast to tips with ...
Diamond Filter Tips play a critical role in preventing aerosol-borne contamination. Also available sterilized (no need to autoclave) and certified free of detectable RNase, DNase, DNA, RNA, and prote...
... Filters are ideal for PCR ... for any work where aerosol ... designed for pipetting DNA/RNA solutions, ... other. For applications requiring absolute ...
Medicine Products: